Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors

Phase 1, open-label, multicenter, dose escalation safety and tolerability study of oncolytic virus OVV-01 in advanced solid tumors

Background OVV-01 is a genetically engineered vesicular stomatitis virus oncolytic virus designed to selectively amplify in tumor cells and express tumor-associated antigen NY-ESO-1. This study was designed to evaluate the safety, tolerability, and efficacy of OVV-01 in patients with advanced solid...

Full description

Saved in:
Bibliographic Details
Main Authors: Yan Wang, Ning Li, Qiang Lin, Fan Li, Fan Zhang, Shuhang Wang, Yingqi Hua, Hui Wu, Liang Ma, Yinying Lu, Haitao Liu, Peng Yuan, Chongren Wang, Yanjie Han, Dongqing Zuo, Yu Lv, Mengxiong Sun, Ruirong Yuan, Guoqing Zhou
Format: Article
Language:English
Published: BMJ Publishing Group 2025-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/13/6/e011517.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://jitc.bmj.com/content/13/6/e011517.full

Similar Items